KKR Real Est Finance Tr Stock (NYSE: KREF)

KKR Real Est Finance Tr (NYSE:KREF) Stock

KKR REAL ESTATE FINANCE TRUS

KKR Real Estate Finance

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

JP Morgan analyst Jeremy Tonet maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Overweight and raises the price target from $100 to $102.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Entergy, Raises Price Target to $102

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are trading marginally lower Tuesday morning, extending a pullback that saw the stock shed around 5% on Monday. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/PLUG/news">need to know</a>.
What To Know: The decline tempers a recent rally, though the stock remains up approximately 8% over the past five sessions as investors digest a mix of positive operational news and potential financing headwinds.
The recent surge was fueled by a number of key developments. Plug <a href="https://www.benzinga.com/pressreleases/25/07/g46314935/plug-power-extends-strategic-hydrogen-supply-agreement-with-multi-year-contract-and-improved-econo">announced</a> a renewed and expanded long-term hydrogen supply agreement with a major U.S. industrial gas partner.
CEO Andy Marsh called the deal, which secures lower-cost hydrogen through 2030, a "win for… our margin profile." Sentiment was also boosted by President Donald Trump signing the "One Big Beautiful Bill," which extended the 45V clean hydrogen tax credit deadline by two years, easing financing timelines for key projects.
However, <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46398722/plug-powers-hot-streak-stalls-as-wall-street-frets-over-warrant-surprise">pressure mounted</a> following a July 9 prospectus filing. The filing registered up to 31.5 million shares for potential resale by a selling stockholder. 
While Plug Power will not receive direct proceeds from the share sales, the move has stoked fresh investor concerns about potential share dilution, capping the recent rally and contributing to the current downward pressure on the stock.
Benzinga Edge Rankings: According to proprietary data from <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a>, which provides scores to help investors identify strong and weak stocks, Plug Power presents a distinct profile. The company scores exceptionally high on Value, with a rating of 74.30, suggesting that its stock may be undervalued based on key financial metrics. 
In sharp contrast, PLUG receives very low scores for both Momentum (8.32) and Growth (15.33), indicating significant weakness in its recent price performance and fundamental growth trajectory.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Plug shares are down 1.89% at $1.54 Tuesday morning. The stock has a 52-week high of $3.34 and a 52-week low of 69 cents.
<h2 class="wp-block-heading">How To Buy PLUG Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Plug Power&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46300500/trumps-hydrogen-lifeline-could-revive-plug-powers-stalled-plans">Trump&#8217;s Hydrogen Lifeline Could Revive Plug Power&#8217;s Stalled Plans</a></li>
</ul>
Image: Shutterstock

PLUG

Plug Power Stock Is Sliding Tuesday: What's Going On?

WIIM

SKYQ

Sky Quarry shares are trading higher after the company announced it will establish a digital asset treasury.

<a href="https://www.bloomberg.com/news/articles/2025-07-15/carney-hints-tariffs-will-stay-sees-talks-with-us-ramping-up?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-15/carney-hints-tariffs-will-stay-sees-talks-with-us-ramping-up?embedded-checkout=true</a>

Macro Notification

Politics

General

'Carney Hints Tariffs Will Stay, Sees Talks With US Ramping Up'- Bloomberg

JP Morgan analyst Jeremy Tonet maintains Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) with a Neutral and raises the price target from $122 to $127.

JP Morgan Maintains Neutral on Duke Energy, Raises Price Target to $127

AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) will release earnings results for the fourth quarter, after the <a href="https://www.benzinga.com/quote/AIR/earnings">closing bell on Wednesday, July 16</a>.
Analysts expect the Wood Dale, Illinois-based company to report quarterly earnings at $1.01 per share, up from 88 cents per share in the year-ago period. AAR projects to report quarterly revenue at $695.81 million, compared to $656.5 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 7, AAR named Sharon Purnell Senior Vice President and Chief Human Resources Officer.
AAR shares fell 0.2% to close at $74.72 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/air/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Truist Securities analyst Michael Ciarmoli maintained a Buy rating and raised the price target from $78 to $81 on July 11, 2025. This analyst has an accuracy rate of 83%.</li>
<li>Keybanc analyst Michael Leshock maintained an Overweight rating and cut the price target from $83 to $80 on April 2, 2025. This analyst has an accuracy rate of 84%.</li>
<li>RBC Capital analyst Ken Herbert reiterated an Outperform rating with a price target of $75 on Nov. 4, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Benchmark analyst Josh Sullivan reiterated a Buy rating with a price target of $83 on Sept. 24, 2025. This analyst has an accuracy rate of 88%.</li>
<li>Stifel analyst Bert Subin maintained a Buy rating and cut the price target from $86 to $85 on July 19, 2024. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying AIR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/air/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="623" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15053748/image-165-1024x623.png" alt="" class="wp-image-985527" style="width:616px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15053748/image-165-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15053748/image-165-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15053748/image-165-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15053748/image-165.png 1040w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

AAR Likely To Report Higher Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Raymond James analyst David Hicks maintains Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) with a Strong Buy and raises the price target from $50 to $55.

Raymond James Maintains Strong Buy on Knight-Swift, Raises Price Target to $55

JP Morgan analyst Jeremy Tonet maintains DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>) with a Neutral and raises the price target from $145 to $147.

JP Morgan Maintains Neutral on DTE Energy, Raises Price Target to $147

CRML

Critical Metals shares are trading higher after the company announced it has commenced its Tanbreez resource diamond drilling program in Greenland.

Raymond James analyst Patrick Tyler Brown maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Strong Buy and raises the price target from $258 to $270.

Raymond James Maintains Strong Buy on Union Pacific, Raises Price Target to $270

Today, WWE, part of TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), and Fanatics Betting and Gaming, a subsidiary of Fanatics, a global digital sports platform, announced an exclusive multi-year licensing agreement for Fanatics Betting and Gaming to produce and distribute WWE-themed online casino games in the United States.
Under the terms of this agreement, Fanatics Betting and Gaming will have a license to produce WWE-themed online casino games exclusively for Fanatics Casino, which is available on <a href="https://www.globenewswire.com/Tracker?data=GZKfAxPupYqojInnKlI9axLpRNfvsidacDf6ezrc6JClxNes0Ijse9Dv-fHFrylg-lnpK8ugEiTJ9lE2H6UqNSbJmYnC_YU3VCFzDwPLJk5SLwxduZh9GT9mpQC58n7l">iOS</a>, <a href="https://www.globenewswire.com/Tracker?data=1t-r_LxjU-sjZTEWr_D4itrVzPSy84UAAYsmRC4gcu5OEIKbeSFVerajtmqk0WpOjxl_PiiPjhyF1h5K6pSL5Lv5VAphU0zuvyDEgirck4ZCS_j_x1h74-86hoXT1XSA0z1N5UHCRu7iZ6v1taVuIg==">Android</a> and <a href="https://www.globenewswire.com/Tracker?data=VapFGfJeQTUJtIg0gTJX-hDei8oIDL3t3bxarvsBYfvzGR1LHIov5UKwj0CuvszJtbK5kSbO9YVKaNtYs4FwFA==">web</a> in Michigan, New Jersey, Pennsylvania and West Virginia. The officially licensed WWE online casino games will launch at the end of July in time for SummerSlam, which takes place across two nights on Saturday, August 2 and Sunday, August 3 at MetLife Stadium in New Jersey.

WWE and Fanatics Strike Exclusive Deal To Launch WWE-Themed Online Casino Games In U.S.

Raymond James analyst Patrick Brown maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Outperform and raises the price target from $33 to $37.

Raymond James Maintains Outperform on CSX, Raises Price Target to $37

Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) gained on Tuesday in solidarity with CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) after the latter&nbsp;announced <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46410852/coreweave-commits-6-billion-to-us-ai-infrastructure-in-lancaster" rel="noreferrer noopener">plans to&nbsp;invest</a> up to $6 billion in building an AI data center in Lancaster, Pennsylvania.&nbsp;
Initially sized at 100 megawatts and expandable to 300 MW, the facility will be one of the region&#8217;s first large-scale AI centers. CoreWeave&#8217;s broader U.S. network consists of 33 data centers.
The company will unveil the project at a CEO roundtable with&nbsp;President Donald Trump&nbsp;during Senator Dave McCormick&#8217;s Energy and Innovation Summit at Carnegie Mellon University.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46306575/why-coreweaves-9-billion-deal-isnt-about-chips" target="_blank" rel="noreferrer noopener">Why CoreWeave&#8217;s $9 Billion Deal Isn&#8217;t About Chips</a>
CoreWeave CEO&nbsp;Michael Intrator&nbsp;said the data center will generate 600 skilled jobs and scale to 175 permanent roles.
CoreWeave will operate the center in partnership with Chirisa Technology Parks and Machine Investment Group. Trump is reportedly looking to unveil a <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46412125/trumps-latest-move-on-ai-and-china-propels-chip-stocks" rel="noreferrer noopener">major initiative on</a> Tuesday near Pittsburgh, Pennsylvania, detailing plans for approximately $70 billion in new investments in artificial intelligence and energy infrastructure.
Core Scientific delivers blockchain infrastructure and hosts digital assets, helping cryptocurrency miners improve their efficiency and profits.
CoreWeave provides specialized cloud computing services focusing on high-performance, GPU-accelerated infrastructure tailored for AI and machine learning. The company operates a cloud platform built to handle large-scale, compute-heavy workloads. It is widely recognized for its deep expertise in deploying Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) GPUs.
CoreWeave <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280108/coreweave-core-scientific-shares-move-lower-on-9-billion-all-stock-deal" target="_blank" rel="noreferrer noopener">agreed to acquire</a> Core Scientific in a definitive all-stock merger deal last week. The transaction values Core Scientific at $9 billion, or $20.40 per share.
By acquiring Core Scientific&#8217;s high-performance data center infrastructure, CoreWeave will gain control of approximately 1.3 gigawatts of power capacity, with more than 1 GW available for future expansion.
Price Actions: CoreWeave stock is up 4.42% at $14.17 last check on Tuesday. CRWV stock is up 8.13%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46399600/nebius-emerges-as-neutral-ai-cloud-alternative-deepens-ties-with-nvidia-openai-microsoft-analyst" target="_blank" rel="noreferrer noopener">Nebius Emerges As Neutral AI Cloud Alternative, Deepens Ties With Nvidia, OpenAI, Microsoft: Analyst</a></li>
</ul>
Image: Shutterstock

Government

Tech

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

NVDA

CoreWeave's $6 Billion AI Bet Boosts Core Scientific Shares Ahead Of $9 Billion Merger Deal

JP Morgan analyst Jeremy Tonet maintains Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) with a Underweight and raises the price target from $53 to $56.

JP Morgan Maintains Underweight on Dominion Energy, Raises Price Target to $56

On Monday, the U.S. Food and Drug Administration (FDA) agreed to review GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">who are at increased risk</a>.
GSK's RSV vaccine is approved in the U.S. to prevent lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, as well as those aged 50-59 years at increased risk for LRTD caused by RSV.
RSV, a common contagious virus affecting the lungs and breathing passages, impacts an estimated 64 million people of all ages globally every year. More than 125 million adults in the U.S. are under 50. An estimated 21 million of these people have at least one diagnosed risk factor for severe RSV infection, such as chronic obstructive pulmonary disease, asthma, congestive heart failure, and coronary heart disease.
The regulatory submission is <a href="https://us.gsk.com/en-us/media/press-releases/fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine-arexvy/" target="_blank" rel="noreferrer noopener">supported</a> by a Phase 3b trial evaluating immune response and safety in adults aged 18-49 who are at increased risk compared to adults aged 60 and above.
The safety and reactogenicity data were consistent with those from the Phase 3 program, which supported the vaccine&#8217;s initial approval in the U.S.
A regulatory decision by the FDA on this submission is expected in the first half of 2026.
In June, the FDA expanded approval of Moderna Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk <a href="https://www.benzinga.com/news/health-care/25/06/45921359/fda-expands-modernas-rsv-vaccine-use-to-at-risk-adults-aged-18-59-amid-cdc-panel-shake-up" target="_blank" rel="noreferrer noopener">for disease</a>. That same month, the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Enflonsia (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age who are born during or entering their first RSV season.
With a <a target="_blank" href="https://www.cdc.gov/media/releases/2025/2025-cdcs-advisory-committee-on-immunization-concludes-meeting-with-joint-statement.html" rel="noreferrer noopener">five-to-two </a>majority, RFK Jr.'s newly constituted committee made its first ruling. This body was formed after RFK Jr. entirely replaced the previous 17-member panel <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46136734/rfk-jrs-cdc-panel-recommends-mercks-rsv-shot-for-infants" rel="noreferrer noopener">with his selections</a>.
Also, in June, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced that it will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and <a href="https://www.benzinga.com/news/health-care/25/06/45839621/beyfortus-output-tripled-as-sanofi-astrazeneca-scale-up-for-rsv-season" target="_blank" rel="noreferrer noopener">runs through March</a>.
In collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Sanofi has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Last week, GSK announced it has started shipping doses of its trivalent seasonal influenza vaccines to U.S. healthcare providers and pharmacies in preparation for the 2025-26 flu season.
This immediately follows FDA licensing and approval of the lot release. FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people <a href="https://www.benzinga.com/pressreleases/25/07/b46342250/gsk-begins-shipping-influenza-vaccine-doses-for-the-2025-26-flu-season" target="_blank" rel="noreferrer noopener">six months and older</a>.
Price Action: GSK stock is down 1.36% at $37.77 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46410829/analyst-with-sell-rating-on-aapl-stock-warns-tim-cooks-company-is-unprepared-for-something-that-transformational" target="_blank" rel="noreferrer noopener">Analyst With Sell Rating On AAPL Stock Warns Tim Cook&#8217;s Company &#8216;Is Unprepared For Something That Transformational&#8217;</a></li>
</ul>
Photo: Shutterstock

Health Care

MRNA

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults

Raymond James analyst Patrick Tyler Brown maintains JB Hunt Transport Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) with a Outperform and raises the price target from $155 to $165.

JBHT

Raymond James Maintains Outperform on JB Hunt Transport Servs, Raises Price Target to $165

Shares of Enovix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) are trading higher Tuesday morning. The high-performance battery company issued <a href="https://www.benzinga.com/pressreleases/25/07/g46413785/enovix-releases-supplemental-faq-to-support-warrant-dividend-distribution">new guidance</a> regarding its upcoming warrant dividend distribution.
What To Know: The company released a supplemental Frequently Asked Question document to address logistical and eligibility concerns from shareholders and brokers ahead of the July 17, record date.
A key point of clarification involves shareholders who hold ENVX stock in margin accounts. Enovix CFO Ryan Benton <a href="https://www.benzinga.com/pressreleases/25/07/g46413785/enovix-releases-supplemental-faq-to-support-warrant-dividend-distribution">warned</a> that brokerage practices like securities lending could prevent these investors from receiving their warrants unless they take proactive steps. The company is urging shareholders to contact their brokers directly to confirm their account status and ensure eligibility for the distribution.
Under the terms, stockholders will receive one warrant for every seven shares of common stock held. The warrants will expire on October 1, 2026, unless an early expiration condition is met. 
This condition is triggered if the stock&#8217;s volume-weighted average price equals or exceeds $10.50 for twenty out of any thirty consecutive trading days.
What Else: Enovix stock is likely rising primarily because its new guidance on the upcoming warrant dividend is creating a potential short squeeze dynamic. The company clarified that shareholders with margin accounts must recall any loaned-out shares to be eligible for the warrants as of the July 17 record date. 
This action forces short sellers, who had borrowed those shares, to buy them back on the open market to cover their positions. According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Enovix has a very high short interest, with 44.609 million shares sold short, which represents a significant 31.16% of its publicly available float.
The resulting surge in buying demand is the main force lifting the stock price, likely amplified by new investors purchasing shares to receive the dividend and by the perception that the warrant issuance is a bullish signal of management&#8217;s confidence.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings for Enovix, the company displays moderate positive momentum with a score of 56.94 out of 100. However, the stock is flagged as being highly overvalued, earning a very low Value score of just 4.71.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ENVX shares are trading higher by 5.9% to $15.52 Tuesday morning. The stock has a 52-week high of $18.68 and a 52-week low of $5.27.
Read Also: <a href="https://www.benzinga.com/content/46378191/5-hot-stocks-with-summer-buybacks-you-can-cash-in-on">5 Hot Stocks With Summer Buybacks You Can Cash In On</a>
<h2 class="wp-block-heading">How To Buy ENVX Stock</h2>
By now you're likely curious about how to participate in the market for Enovix &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Enovix, which is trading at $15.38 as of publishing time, $100 would buy you 6.5 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

ENVX

What's Going On With Enovix (ENVX) Stock Tuesday?

U.S. stocks traded mixed midway through trading, with the Nasdaq gaining more than 100 points on Tuesday.
The Dow traded down 0.57% to 44,204.33 while the NASDAQ gained 0.71% to 20,786.86. The S&amp;P 500 also rose, gaining, 0.01% to 6,269.15.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46413798/morgan-stanley-how-to-earn-500-a-month-from-q2-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q2 Earnings</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, materials stocks dipped by 0.9%.
Top Headline
Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) reported better-than-expected second-quarter adjusted EPS results.
Wells Fargo posted adjusted earnings of $1.54 per share, beating market estimates of $1.40 per share. Wells Fargo reported a net interest income of $11.71 billion on Tuesday, down 2% year over year in the second quarter of 2025.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 143% to $6.43 after the company announced it has entered into a definitive merger agreement with True Health.</li>
<li>Shares of Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) got a boost, surging 87% to $1.2808 after the company announced safety results from its Phase 2 trial of ENV-105 in advanced prostate cancer.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) shares were also up, gaining 57% to $0.2366 after the company announced it is partnering with HYPERCOMMUNITY to deliver an AI-driven VTuber platform.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Ryvyl Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) shares dropped 45% to $0.3552 after the company announced the pricing of its $6 million offering of 15,384,615 shares and warrants at $0.39 per share and accompanying warrant.</li>
<li>Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) were down 42% to $0.4058 after the company announced the pricing of $3.0 million registered direct offering.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was down, falling 19% to $14.15 following downbeat quarterly sales. Keybanc downgraded the stock from Overweight to Sector Weight and Stephens &amp; Co. cut its price target from $28 to $20.</li>
</ul>
Commodities In commodity news, oil traded down 0.5% to $66.66 while gold traded down 0.1% at $3,355.90.
Silver traded down 1.2% to $38.280 on Tuesday, while copper fell 0.3% to $5.5320.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.09%, while Spain's IBEX 35 Index fell 1.16%. London's FTSE 100 fell 0.23%, Germany's DAX 40 slipped 0.09% and France's CAC 40 fell 0.21% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.55%, Hong Kong's Hang Seng gaining 1.60%, China's Shanghai Composite falling 0.42% and India's BSE Sensex gaining 0.39%.
Economics
The New York Empire State Manufacturing Index jumped to 5.5 in July, compared to a reading of -16.0 in June and topping market estimates of -9.0.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46414893/meta-to-rally-around-8-here-are-10-top-analyst-forecasts-for-tuesday">Meta To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

BLMZ

KAPA

RANI

RVYL

Longevity Health Holdings, Inc. - Common Stock

XAGE

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

Raymond James analyst David Hicks maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Outperform and lowers the price target from $114 to $111.

CHRW

Raymond James Maintains Outperform on C.H. Robinson Worldwide, Lowers Price Target to $111

JP Morgan analyst Jeremy Tonet maintains CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Neutral and raises the price target from $39 to $40.

Comments

KKR Real Est Finance Tr

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL